Change in cardiac function (change in peak systolic radial strain in LV lateral wall segments) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function (change in systolic radial strain rate LV inferolateral wall) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function: change (decline) from baseline in left ventricular strain · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Change in Ejection fraction (%) · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Improvements in quality of life measures · boys with DMD and left ventricular ejection fraction 45% or more
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD and left ventricular ejection fraction 45% or more
It is very uncertain whether eplerenone (25 mg daily) changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Improvements in quality of life measures · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
Prophylactic perindopril (2 mg to 4 mg daily) showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Cardiac function · patients with established cardiomyopathy in DMD
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · patients with established cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · patients with established cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with established cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function (change in fractional shortening) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Overall clinical improvement at short‐term · carpal tunnel syndrome
2 findings from 1 review
Overall clinical improvement at long‐term · carpal tunnel syndrome
3 findings from 1 review
no estimate extracted
1 study · 77 participants
Very low
RR 1.34 [1.05, 1.72]
1 study · 77 participants
Very low
RR 1.73 [1.22, 2.45]
1 study · 77 participants
Very low